Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05607550




Registration number
NCT05607550
Ethics application status
Date submitted
31/10/2022
Date registered
7/11/2022
Date last updated
16/05/2024

Titles & IDs
Public title
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
Scientific title
A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
Secondary ID [1] 0 0
2022-502977-41-00
Secondary ID [2] 0 0
FURMO-004
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Metastatic Non-Small Cell Lung Cancer 0 0
Advanced Non-Small Cell Lung Cancer 0 0
EGFR Exon 20 Mutations 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lung - Mesothelioma
Cancer 0 0 0 0
Lung - Non small cell
Cancer 0 0 0 0
Lung - Small cell

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - furmonertinib 240 mg oral, daily
Treatment: Drugs - furmonertinib 160 mg oral, daily
Treatment: Drugs - platinum-based chemotherapy

Experimental: furmonertinib 240 mg -

Experimental: furmonertinib 160 mg -

Active Comparator: platinum-based chemotherapy - carboplatin or cisplatin based on investigator's choice + pemetrexed intravenously


Treatment: Drugs: furmonertinib 240 mg oral, daily
furmonertinib tablet

Treatment: Drugs: furmonertinib 160 mg oral, daily
furmonertinib tablet

Treatment: Drugs: platinum-based chemotherapy
(carboplatin or cisplatin based on investigator's choice) + pemetrexed intravenously (IV)
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression Free Survival (PFS) determined by blinded independent central review (BICR)
Timepoint [1] 0 0
Up to 32 months after first dose
Secondary outcome [1] 0 0
Overall Survival (OS)
Timepoint [1] 0 0
Up to 62 months after first dose
Secondary outcome [2] 0 0
PFS determined by investigator assessment
Timepoint [2] 0 0
Up to 36 months after first dose
Secondary outcome [3] 0 0
Overall response rate (ORR)
Timepoint [3] 0 0
Up to 36 months after first dose
Secondary outcome [4] 0 0
Duration of response (DOR)
Timepoint [4] 0 0
Up to 36 months after first dose
Secondary outcome [5] 0 0
Time to second Progression Free Survival (PFS2)
Timepoint [5] 0 0
Up to 36 months after first dose
Secondary outcome [6] 0 0
PFS by blinded independent central review (BICR) in patients with a history or presence of brain metastases at baseline
Timepoint [6] 0 0
Up to 36 months after first dose
Secondary outcome [7] 0 0
Time to central nervous system (CNS) metastases by BICR
Timepoint [7] 0 0
Randomization up to =30 days after last dose
Secondary outcome [8] 0 0
CNS ORR evaluated by BICR
Timepoint [8] 0 0
Randomization up to =30 days after last dose
Secondary outcome [9] 0 0
CNS DOR evaluated by BICR
Timepoint [9] 0 0
Randomization up to =30 days after last dose
Secondary outcome [10] 0 0
CNS PFS evaluated by BICR
Timepoint [10] 0 0
Randomization up to =30 days after last dose
Secondary outcome [11] 0 0
Change in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (QLQ-C30)
Timepoint [11] 0 0
Randomization up to =30 days after last dose
Secondary outcome [12] 0 0
Change in EORTC QLQ Lung Cancer Module Core 13 (QLQ LC13)
Timepoint [12] 0 0
Randomization up to =30 days after last dose
Secondary outcome [13] 0 0
Change in Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC SAQ)
Timepoint [13] 0 0
Randomization up to =30 days after last dose
Secondary outcome [14] 0 0
Number of incidence and severity of adverse events (AEs) as a measure of safety and tolerability of Furmonertinib
Timepoint [14] 0 0
Up to 36 months after first dose
Secondary outcome [15] 0 0
Plasma concentrations of furmonertinib and its major metabolite (AST5902)
Timepoint [15] 0 0
Up to 36 months after first dose

Eligibility
Key inclusion criteria
Key

- Histologically or cytologically documented, locally advanced or metastatic
non-squamous Non-Small Cell Lung Cancer (NSCLC) not amenable to curative surgery or
radiotherapy.

- Documented results of the presence of an Epidermal Growth Factor Receptor (EGFR) exon
20 insertion mutation in tumor tissue or blood from local or central testing.

- No prior systemic anticancer therapy regimens received for locally advanced or
metastatic Non-Small Cell Lung Cancer (NSCLC) including prior treatment with any
Epidermal Growth Factor Receptor (EGFR)-targeting agents (e.g., previous (EGFR) TKIs,
monoclonal antibodies, or bispecific antibodies).

- Patients who have received prior neo-adjuvant and/or adjuvant chemotherapy,
immunotherapy, or chemo radiotherapy for non-metastatic disease (excluding EGFR-TKIs)
must have experienced a treatment free interval of at least 12 months.

- Patients with a history of treated CNS metastases or new asymptomatic CNS metastases
are eligible.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/06/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
15/02/2028
Actual
Sample size
Target
375
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
ArriVent Investigative Site - Heidelberg
Recruitment hospital [2] 0 0
Arrivent Investigative Site - Blacktown
Recruitment hospital [3] 0 0
Arrivent Investigative Site - St Leonards
Recruitment hospital [4] 0 0
Arrivent Investigative Site - Woolloongabba
Recruitment postcode(s) [1] 0 0
3084 - Heidelberg
Recruitment postcode(s) [2] 0 0
2148 - Blacktown
Recruitment postcode(s) [3] 0 0
NSW 2065 - St Leonards
Recruitment postcode(s) [4] 0 0
4102 - Woolloongabba
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Connecticut
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Indiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Maryland
Country [10] 0 0
United States of America
State/province [10] 0 0
Massachusetts
Country [11] 0 0
United States of America
State/province [11] 0 0
Michigan
Country [12] 0 0
United States of America
State/province [12] 0 0
Missouri
Country [13] 0 0
United States of America
State/province [13] 0 0
Nebraska
Country [14] 0 0
United States of America
State/province [14] 0 0
New Jersey
Country [15] 0 0
United States of America
State/province [15] 0 0
New York
Country [16] 0 0
United States of America
State/province [16] 0 0
North Carolina
Country [17] 0 0
United States of America
State/province [17] 0 0
Ohio
Country [18] 0 0
United States of America
State/province [18] 0 0
Oklahoma
Country [19] 0 0
United States of America
State/province [19] 0 0
Oregon
Country [20] 0 0
United States of America
State/province [20] 0 0
Pennsylvania
Country [21] 0 0
United States of America
State/province [21] 0 0
South Carolina
Country [22] 0 0
United States of America
State/province [22] 0 0
South Dakota
Country [23] 0 0
United States of America
State/province [23] 0 0
Tennessee
Country [24] 0 0
United States of America
State/province [24] 0 0
Texas
Country [25] 0 0
United States of America
State/province [25] 0 0
Utah
Country [26] 0 0
United States of America
State/province [26] 0 0
Virginia
Country [27] 0 0
United States of America
State/province [27] 0 0
Washington
Country [28] 0 0
United States of America
State/province [28] 0 0
Wisconsin
Country [29] 0 0
Brazil
State/province [29] 0 0
Bahia
Country [30] 0 0
Brazil
State/province [30] 0 0
Minas Gerais
Country [31] 0 0
Brazil
State/province [31] 0 0
Rio Grande
Country [32] 0 0
Brazil
State/province [32] 0 0
RJ
Country [33] 0 0
Brazil
State/province [33] 0 0
RS
Country [34] 0 0
Brazil
State/province [34] 0 0
Sao Paulo
Country [35] 0 0
Brazil
State/province [35] 0 0
SC Cep
Country [36] 0 0
Brazil
State/province [36] 0 0
São Paulo/SP
Country [37] 0 0
Brazil
State/province [37] 0 0
Taubate SP
Country [38] 0 0
Brazil
State/province [38] 0 0
Porto Alegre
Country [39] 0 0
China
State/province [39] 0 0
Beijing
Country [40] 0 0
China
State/province [40] 0 0
Hai City
Country [41] 0 0
China
State/province [41] 0 0
Hangzhou
Country [42] 0 0
China
State/province [42] 0 0
Hebei
Country [43] 0 0
China
State/province [43] 0 0
Hefei
Country [44] 0 0
China
State/province [44] 0 0
Henan
Country [45] 0 0
China
State/province [45] 0 0
Jilin
Country [46] 0 0
China
State/province [46] 0 0
Lingang Economic And Technological Development Zo
Country [47] 0 0
China
State/province [47] 0 0
Meizhou City, Guangdong Province
Country [48] 0 0
China
State/province [48] 0 0
Shanghai
Country [49] 0 0
China
State/province [49] 0 0
Taiyuan
Country [50] 0 0
China
State/province [50] 0 0
Anyang
Country [51] 0 0
China
State/province [51] 0 0
Changchun
Country [52] 0 0
China
State/province [52] 0 0
Changsha
Country [53] 0 0
China
State/province [53] 0 0
Chengdu
Country [54] 0 0
China
State/province [54] 0 0
Chenzhou
Country [55] 0 0
China
State/province [55] 0 0
Chongqing
Country [56] 0 0
China
State/province [56] 0 0
Guangzhou
Country [57] 0 0
China
State/province [57] 0 0
Harbin
Country [58] 0 0
China
State/province [58] 0 0
Huai'an
Country [59] 0 0
China
State/province [59] 0 0
Huizhou
Country [60] 0 0
China
State/province [60] 0 0
Jinan
Country [61] 0 0
China
State/province [61] 0 0
Jining
Country [62] 0 0
China
State/province [62] 0 0
Lanzhou
Country [63] 0 0
China
State/province [63] 0 0
Lishui
Country [64] 0 0
China
State/province [64] 0 0
Luoyang
Country [65] 0 0
China
State/province [65] 0 0
Nanchang
Country [66] 0 0
China
State/province [66] 0 0
Nanjing
Country [67] 0 0
China
State/province [67] 0 0
Ningbo
Country [68] 0 0
China
State/province [68] 0 0
Shantou
Country [69] 0 0
China
State/province [69] 0 0
Shenyang
Country [70] 0 0
China
State/province [70] 0 0
Shenzhen
Country [71] 0 0
China
State/province [71] 0 0
Taoyuan
Country [72] 0 0
China
State/province [72] 0 0
Tianjin
Country [73] 0 0
China
State/province [73] 0 0
Weihui
Country [74] 0 0
China
State/province [74] 0 0
Wuhan
Country [75] 0 0
China
State/province [75] 0 0
Xiamen
Country [76] 0 0
China
State/province [76] 0 0
Xianyang
Country [77] 0 0
China
State/province [77] 0 0
Xinxiang
Country [78] 0 0
China
State/province [78] 0 0
Xuzhou
Country [79] 0 0
China
State/province [79] 0 0
Zhengzhou
Country [80] 0 0
France
State/province [80] 0 0
Caen
Country [81] 0 0
France
State/province [81] 0 0
Lyon
Country [82] 0 0
France
State/province [82] 0 0
Marseille
Country [83] 0 0
France
State/province [83] 0 0
Toulouse
Country [84] 0 0
France
State/province [84] 0 0
Villejuif
Country [85] 0 0
Israel
State/province [85] 0 0
Be'er Sheva
Country [86] 0 0
Israel
State/province [86] 0 0
Haifa
Country [87] 0 0
Israel
State/province [87] 0 0
Jerusalem
Country [88] 0 0
Italy
State/province [88] 0 0
Milan
Country [89] 0 0
Italy
State/province [89] 0 0
Rome
Country [90] 0 0
Italy
State/province [90] 0 0
Bari
Country [91] 0 0
Italy
State/province [91] 0 0
Meldola
Country [92] 0 0
Italy
State/province [92] 0 0
Milano
Country [93] 0 0
Japan
State/province [93] 0 0
Fukuoka
Country [94] 0 0
Japan
State/province [94] 0 0
Akashi
Country [95] 0 0
Japan
State/province [95] 0 0
Hirakata
Country [96] 0 0
Japan
State/province [96] 0 0
Kashiwa
Country [97] 0 0
Japan
State/province [97] 0 0
Nagoya
Country [98] 0 0
Japan
State/province [98] 0 0
Sapporo-shi
Country [99] 0 0
Japan
State/province [99] 0 0
Sendai
Country [100] 0 0
Japan
State/province [100] 0 0
Shizuoka
Country [101] 0 0
Japan
State/province [101] 0 0
Tokyo
Country [102] 0 0
Japan
State/province [102] 0 0
Ube
Country [103] 0 0
Japan
State/province [103] 0 0
Yokohama
Country [104] 0 0
Japan
State/province [104] 0 0
Osaka-sayama
Country [105] 0 0
Korea, Republic of
State/province [105] 0 0
Seoul
Country [106] 0 0
Korea, Republic of
State/province [106] 0 0
Busan
Country [107] 0 0
Korea, Republic of
State/province [107] 0 0
Hwasun
Country [108] 0 0
Malaysia
State/province [108] 0 0
Pulau Pinang
Country [109] 0 0
Malaysia
State/province [109] 0 0
Cheras
Country [110] 0 0
Malaysia
State/province [110] 0 0
Kota Bharu
Country [111] 0 0
Malaysia
State/province [111] 0 0
Kuala Lumpur
Country [112] 0 0
Malaysia
State/province [112] 0 0
Kuching
Country [113] 0 0
Netherlands
State/province [113] 0 0
Amsterdam
Country [114] 0 0
Netherlands
State/province [114] 0 0
Harderwijk
Country [115] 0 0
Philippines
State/province [115] 0 0
Cebu
Country [116] 0 0
Philippines
State/province [116] 0 0
Davao City
Country [117] 0 0
Philippines
State/province [117] 0 0
Manila
Country [118] 0 0
Philippines
State/province [118] 0 0
Pasig
Country [119] 0 0
Singapore
State/province [119] 0 0
Singapore
Country [120] 0 0
Spain
State/province [120] 0 0
Malaga
Country [121] 0 0
Spain
State/province [121] 0 0
A Coruña
Country [122] 0 0
Spain
State/province [122] 0 0
Barcelona
Country [123] 0 0
Spain
State/province [123] 0 0
Madrid
Country [124] 0 0
Spain
State/province [124] 0 0
Valencia
Country [125] 0 0
Taiwan
State/province [125] 0 0
Chang Hua
Country [126] 0 0
Taiwan
State/province [126] 0 0
Kaohsiung
Country [127] 0 0
Taiwan
State/province [127] 0 0
Taichung
Country [128] 0 0
Taiwan
State/province [128] 0 0
Tainan
Country [129] 0 0
Taiwan
State/province [129] 0 0
Taipei
Country [130] 0 0
Thailand
State/province [130] 0 0
Bangkok
Country [131] 0 0
Thailand
State/province [131] 0 0
Hat Yai
Country [132] 0 0
United Kingdom
State/province [132] 0 0
Surrey
Country [133] 0 0
United Kingdom
State/province [133] 0 0
London
Country [134] 0 0
United Kingdom
State/province [134] 0 0
Manchester
Country [135] 0 0
United Kingdom
State/province [135] 0 0
Sutton

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
ArriVent BioPharma, Inc.
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Allist Pharmaceuticals, Inc.
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety
of furmonertinib (firmonertinib) at 2 dose levels (160 mg once daily [QD] and 240 mg QD)
compared to platinum-based chemotherapy in previously untreated patients with locally
advanced or metastatic non-squamous Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth
Factor Receptor (EGFR) exon 20 insertion mutations. A target of approximately 375 patients
will be randomized in a 1:1:1 ratio to treatment with furmonertinib 240 mg QD, furmonertinib
160 mg QD, or platinum-based chemotherapy.
Trial website
https://clinicaltrials.gov/ct2/show/NCT05607550
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Morgan Lam
Address 0 0
ArriVent BioPharm
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Vanessa Esquibel
Address 0 0
Country 0 0
Phone 0 0
6195403451
Fax 0 0
Email 0 0
FURMO004CT@arrivent.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT05607550